Scientists have discovered a previously unknown mechanism by which apolipoprotein E, a molecule whose mutation is linked to Alzheimer's disease (AD), stimulates degradation of sticky amyloid beta (A-beta) protein within the brain. The research, published by Cell Press in the June 12 issue of the journal Neuron, may lead to a powerful new therapy for this devastating disease.
One of the primary characteristics of AD is the accumulation and deposition of neuron-damaging clumps of A-beta protein. Apolipoprotein E (ApoE), a cholesterol transport protein, is known to be a key regulator of brain A-beta levels, and it is likely that processes that regulate ApoE activity will influence A-beta deposition and clearance. "An isoform of ApoE, ApoE4, has been shown to confer dramatically increased risk for late-onset AD; however, the basis for this remains one of the major unanswered questions of disease pathogenesis," writes study author Dr. Gary E. Landreth from the Alzheimer Research Laboratory at Case Western Reserve University School of Medicine in Cleveland, Ohio.
Dr. Landreth and colleagues sought to unravel the link between ApoE, A-beta clearance in the brain, and an enhanced risk for AD. The researchers found that ApoE profoundly enhanced the intracellular and extracellular degradation of A-beta. This enhancement varied for different isoforms of ApoE with the ApoE4 isoform exhibiting an impaired ability to promote A-beta degradation when compared to other ApoE isoforms. The number of lipid molecules associated with ApoE was also critical to its ability to stimulate A-beta degradation. Activation of liver X receptors (LXRs) to enhance expression of lipidated ApoE significantly facilitated A-beta degradation. Importantly, use of an LXR agonist to increase lipidated forms of ApoE in a mouse model of AD resulted in reduced A-beta plaque levels and an improvement in contextual memory.
The results of this study document a major role for ApoE in the stimulation of A-beta degradation within the brain and highlight the importance of lipidation to the function of ApoE. This work also explains the previous observation that inactivation of a gene which helps the brain to process lipids (called Abca1) resulted in decreased levels of ApoE along with a seemingly paradoxical elevation of A-beta levels and plaque formation in mice. "Our data suggest that therapeutic agents that increase the levels of lipidated forms of ApoE, including LXR agonists, represent a potentially efficacious therapy for AD," concludes Dr. Landreth.
Source: Cell Press
Related stories:
New study finds healthy children of Alzheimer patients show early brain changes
Medical College of Wisconsin researchers in Milwaukee have reported that children of Alzheimer's patients who are carriers of a genetic risk factor for Alzheimer's disease have neurological changes that are detectable long before clinical symptoms may appear.
Second genetic risk factor for late-onset Alzheimer's disease found
Researchers have discovered the second, strong genetic risk factor for developing late-onset Alzheimer's disease, according to a new report in the June 27th issue of the journal
Cell, a Cell Press publication.
Known Genetic Risk Alzheimer's In Whites Also Places Blacks At Risk
A commonly recognized gene that places one at risk for Alzheimer’s disease does not discriminate between blacks and whites, according to new research led by Florida State University.
Known genetic risk for Alzheimer's in whites also places blacks at risk
A commonly recognized gene that places one at risk for Alzheimer's disease does not discriminate between blacks and whites, according to new research led by Florida State University.
Protein linked to Alzheimer's disease also has role in HIV progression
The apolipoprotein (apo) E4 isoform has been implicated in neurodegeneration in Alzheimer's disease, cardiovascular disease, and stroke. Now, investigators at the Gladstone Institutes, the University of California, San Francisco, the University of Texas Health Science Center at San Antonio, and the Infectious Disease Clinical Research Program, Uniformed Services University, Bethesda, Maryland have shown that this troubling protein is a risk factor for AIDS progression rates and promotes entry of HIV into cells. The study was published in today's issue of the
Proceedings of the National Academy of Sciences USA (PNAS).
Researchers explore the emerging role of infection in Alzheimer's disease
The realization that pathogens can produce slowly progressive chronic diseases has opened new lines of research into Alzheimer's disease. In a special issue of the
Journal of Alzheimer's Disease published May 2008, guest editors Judith Miklossy, from the University of British Columbia, and Ralph N. Martins, from Edith Cowan University and Hollywood Private Hospital, Perth, Western Australia, and a group of experts explore this exciting topic.
Alzheimer's disease risks are gender specific
The risks of developing Alzheimer’s disease differ between the sexes, with stroke in men, and depression in women, critical factors, suggests research published ahead of print in the
Journal of Neurology Neurosurgery and Psychiatry.
Alzheimer's starts earlier for heavy drinkers, smokers
Heavy drinkers and heavy smokers develop Alzheimer’s disease years earlier than people with Alzheimer’s who do not drink or smoke heavily, according to research that will be presented at the American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12–19, 2008.